866-997-4948(US-Canada Toll Free)

Klebsiella pneumoniae Infections-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 86 Pages

Klebsiella pneumoniae Infections-Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Klebsiella pneumoniae Infections-Pipeline Review, H2 2017, provides an overview of the Klebsiella pneumoniae Infections (Infectious Disease) pipeline landscape.

Klebsiella pneumoniae is a Gram-negative bacteria. A Klebsiella pneumoniae infection is caused when the organism is able to enter the lungs. A Klebsiella pneumoniae infection is very common in patients with underlying diseases like diabetes, chronic lung diseases and chronic alcoholics. It is mostly a nosocomial infection that occurs in hospitalized patients with weakened immune system. Symptoms include necrosis, inflammation, hemorrhage, chills, dizziness, high fever, head ache and chest pain. Treatment includes antibiotics and hygiene lifestyle.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Klebsiella pneumoniae Infections-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Klebsiella pneumoniae Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 1, 23 and 7 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Klebsiella pneumoniae Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Klebsiella pneumoniae Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Klebsiella pneumoniae Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Klebsiella pneumoniae Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Klebsiella pneumoniae Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Klebsiella pneumoniae Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Klebsiella pneumoniae Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Klebsiella pneumoniae Infections-Overview 6
Klebsiella pneumoniae Infections-Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Pipeline by Universities/Institutes 11
Products under Development by Companies 12
Products under Development by Universities/Institutes 14
Klebsiella pneumoniae Infections-Therapeutics Assessment 15
Assessment by Target 15
Assessment by Mechanism of Action 17
Assessment by Route of Administration 19
Assessment by Molecule Type 21
Klebsiella pneumoniae Infections-Companies Involved in Therapeutics Development 23
Acies Bio doo 23
Appili Therapeutics 23
Debiopharm International SA 23
Evaxion Biotech ApS 24
F. Hoffmann-La Roche Ltd 24
FOB Synthesis Inc 25
ImmunoClin Corp 25
Innovation Pharmaceuticals Inc 25
Kyorin Pharmaceutical Co Ltd 26
Melinta Therapeutics Inc 26
Nosopharm SAS 26
Peptilogics Inc 27
Pfizer Inc 27
Phico Therapeutics Ltd 28
Sarepta Therapeutics Inc 28
Shionogi & Co Ltd 29
Syntiron LLC 29
Tetraphase Pharmaceuticals Inc 29
Klebsiella pneumoniae Infections-Drug Profiles 31
Antisense Oligonucleotide to Inhibit NDM-1 for Klebsiella Pneumoniae Infections-Drug Profile 31
ASN-300-Drug Profile 32
ATI-1503-Drug Profile 33
CA-824-Drug Profile 34
CC-1807-Drug Profile 35
cefiderocol-Drug Profile 36
Debio-1454-Drug Profile 41
EBX-004-Drug Profile 42
FPI-1465-Drug Profile 43
FSI-1671-Drug Profile 45
FSI-1686-Drug Profile 46
GN Snare-Drug Profile 47
GYR-12-Drug Profile 48
IBN-1-Drug Profile 49
interleukin-22-Drug Profile 50
kelokardin-Drug Profile 51
Klebsiella pneumonia vaccine-Drug Profile 52
Klebsiella pneumoniae vaccine-Drug Profile 53
Klebsiella pneumoniae vaccine-Drug Profile 54
Klebsiella pneumoniae vaccine-Drug Profile 55
mirandamycin-Drug Profile 56
NCL-195-Drug Profile 57
NOSO-95179-Drug Profile 58
Onc-72-Drug Profile 59
OTP-602-Drug Profile 60
Peptides for Infectious Diseases-Drug Profile 61
PT-4-Drug Profile 62
RXP-873-Drug Profile 63
Small Molecule to Inhibit LpxC for Gram-Negative Bacterial Infections-Drug Profile 65
Small Molecules for Bacterial and Fungal Infections-Drug Profile 66
Small Molecules for Bacterial Infections-Drug Profile 67
Small Molecules for Bacterial Infections-Drug Profile 68
Small Molecules for Klebsiella pneumoniae Infections-Drug Profile 69
Small Molecules for Multi-Drug Resistant Gram-Positive and Gram-Negative Bacterial Infections-Drug Profile 70
Small Molecules to Inhibit Lipopolysaccharide for Bacterial and Nosocomial Infections-Drug Profile 71
tebipenem pivoxil-Drug Profile 72
TP-6076-Drug Profile 73
WLBU-2-Drug Profile 75
Klebsiella pneumoniae Infections-Dormant Projects 76
Klebsiella pneumoniae Infections-Discontinued Products 78
Klebsiella pneumoniae Infections-Product Development Milestones 79
Featured News & Press Releases 79
Appendix 82
Methodology 82
Coverage 82
Secondary Research 82
Primary Research 82
Expert Panel Validation 82
Contact Us 82
Disclaimer 83

List of Tables
Number of Products under Development for Klebsiella pneumoniae Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Universities/Institutes, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Acies Bio doo, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Appili Therapeutics, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Debiopharm International SA, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Evaxion Biotech ApS, H2 2017
Klebsiella pneumoniae Infections-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017
Klebsiella pneumoniae Infections-Pipeline by FOB Synthesis Inc, H2 2017
Klebsiella pneumoniae Infections-Pipeline by ImmunoClin Corp, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Innovation Pharmaceuticals Inc, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Kyorin Pharmaceutical Co Ltd, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Melinta Therapeutics Inc, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Nosopharm SAS, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Peptilogics Inc, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Pfizer Inc, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Phico Therapeutics Ltd, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Sarepta Therapeutics Inc, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Shionogi & Co Ltd, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Syntiron LLC, H2 2017
Klebsiella pneumoniae Infections-Pipeline by Tetraphase Pharmaceuticals Inc, H2 2017
Klebsiella pneumoniae Infections-Dormant Projects, H2 2017
Klebsiella pneumoniae Infections-Dormant Projects, H2 2017 (Contd..1), H2 2017
Klebsiella pneumoniae Infections-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Klebsiella pneumoniae Infections, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Top 10 Molecule Types, H2 2017
Number of Products by Stage and Top 10 Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *